ACT NOW: Eliminate Cervical Cancer
A global initiative announced on 17 November 2025 the world is poised with the first World Health Day dedicated to eliminate a cancer. The target of that campaign to eliminate cervical cancer and to do so the WHO initiated the 90-70-90 target for 2030. The goals is
90% of girls vaccinated again HPV by age 15
70% of women screen with a “high performance test“ at age 35 and age 45.
90% of positively diagnosed patience to be receiving the life saving treatment they need.
building the highest performance test to date.
Performance can be measured by many metrics but for us the most important are
Accuracy - Results must give an accurate reflection of the patient risk of developing cancer.
Availability - Can the patient get to the screening center or can the screening center come to them?
Affordability - If the price is too high the availability goes down and so does the chance of helping the patients.
Accessibility - We can have the best tests in the world but if they’re too complex or time consuming the benefits are greatly reduced.
HPV protein expressing cells visualised by PhenoDot
With our prototype assay we’ve been able to tag and visualise cervical cells which are expressing virus proteins. A clear indicator of active HPV infection.
Addressing each performance metric.
Accuracy.
PhenoDot directly detects active HPV infection in cervical samples, providing a more relevant risk assessment than traditional PCR tests and reducing the human error in histology screening. Conventional screening methods are slow and prone to high rates of false positives and negatives.
Availability.
To achieve global screening targets by 2030, screening must be accessible everywhere. PhenoDot simplifies testing so it can be done in mobile clinics, bringing screening directly to patients.
Affordability.
PhenoDot kits requires minimal training and equipment, reducing costs significantly and making screening financially accessible for both patients and providers.
Accessibility.
PhenoDot simple assay can be interpreted visually without specialist training or complex equipment. Sample preparation is easy, and results can be obtained at the point of care in under two hours.
Call to Action
We’re actively looking for collaborators for co-development opportunities for optimisation, clinical validation and to proceed to clinical trials.